Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · IEX Real-Time Price · USD
60.57
+3.47 (6.08%)
At close: May 3, 2024, 4:00 PM
61.74
+1.17 (1.93%)
After-hours: May 3, 2024, 4:26 PM EDT
Keros Therapeutics Employees
Keros Therapeutics had 136 employees on December 31, 2023. The number of employees increased by 31 or 29.52% compared to the previous year.
Employees
136
Change (1Y)
31
Growth (1Y)
29.52%
Revenue / Employee
$1,110
Profits / Employee
-$1,124,941
Market Cap
2.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 136 | 31 | 29.52% |
Dec 31, 2022 | 105 | 45 | 75.00% |
Dec 31, 2021 | 60 | 25 | 71.43% |
Dec 31, 2020 | 35 | 12 | 52.17% |
Dec 31, 2019 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
AMN Healthcare Services | 18,223 |
Teladoc Health | 5,600 |
CONMED | 4,000 |
Ginkgo Bioworks Holdings | 1,218 |
STAAR Surgical Company | 1,115 |
Privia Health Group | 1,102 |
Arvinas | 445 |
Rocket Pharmaceuticals | 268 |
KROS News
- 2 months ago - Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Keros Therapeutics to Develop KER-065 for the Treatment of Obesity - GlobeNewsWire
- 5 months ago - Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire